<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02681328</url>
  </required_header>
  <id_info>
    <org_study_id>16-000055</org_study_id>
    <nct_id>NCT02681328</nct_id>
  </id_info>
  <brief_title>Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules</brief_title>
  <official_title>Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the performance of Afirma GSC and ThyroSeq v.3 in
      indeterminate thyroid nodules to determine which test can allow more patients to avoid
      unnecessary surgery and preserve quality of life. In the initial phase of this study, the
      performance of Afirma GEC and ThyroSeq v.2 were compared.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. All patients undergoing thyroid FNA within the UCLA Health System will be randomized at
           the time of FNA to a single molecular test (GSC or ThyroSeq v.3). In the previous phase
           of the study, patients were randomized to the previous versions of a single molecular
           test (GEC or ThyroSeq v.2).

        2. During the FNA, a sample will be collected for the molecular test.

        3. If the cytology results are indeterminate (Bethesda categories 3 or 4), the molecular
           test will be reflexively sent off.

        4. We will help patients with indeterminate thyroid nodules to establish care with an
           endocrinologist, if they do not already have one. The physicians will make treatment
           recommendations using best practices and incorporating the results of the molecular
           test. We anticipate that most patients with a positive molecular test will undergo
           surgery, while the majority with a negative test will be surveiled.

        5. Patients who undergo surgery will have histopathologic evaluation of the thyroid, which
           will determine whether the index thyroid nodule was benign or malignant.

        6. Patients who do not undergo surgery will have a followup ultrasound at 6 and 12 months,
           or sooner at the discretion of the treating physician.

        7. We will assess thyroid-specific quality of life at baseline (following initial diagnosis
           of an indeterminate thyroid nodule) and during followup (at 6 and 12 months) using the
           short version of Thyroid-Related Patient-Reported Outcome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2016</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Afirma GEC vs. ThyroSeq v.2 in indeterminate thyroid nodules post best practices surgery</measure>
    <time_frame>12 months. [This phase of the study is now completed]</time_frame>
    <description>compare the performance of Afirma GEC and ThyroSeq v.2 in indeterminate thyroid nodules to determine which test can allow more patients to avoid unnecessary surgery and preserve quality of life. (5) Patients who undergo surgery will have histopathologic evaluation of the thyroid, which will determine whether the index thyroid nodule was benign or malignant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2. Afirma GSC vs. ThyroSeq v.3 in indeterminate thyroid nodules post best practices surgery</measure>
    <time_frame>12 months.</time_frame>
    <description>compare the performance of Afirma GSC and ThyroSeq v.3 in indeterminate thyroid nodules to determine which test can allow more patients to avoid unnecessary surgery and preserve quality of life. (5) Patients who undergo surgery will have histopathologic evaluation of the thyroid, which will determine whether the index thyroid nodule was benign or malignant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Avoidance of unnecessary surgeries</measure>
    <time_frame>12 months</time_frame>
    <description>Determine the number of unnecessary surgeries avoided based on the number of false-positive test results, and assess whether this translated into improved quality of life.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Thyroid</condition>
  <arm_group>
    <arm_group_label>Afirma GEC</arm_group_label>
    <description>single molecular test GEC of collected tissue</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ThyroSeq v.2</arm_group_label>
    <description>single molecular test ThyroSeq v.2 of collected tissue</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Afirma GSC</arm_group_label>
    <description>single molecular test GSC of collected tissue</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ThyroSeq v.3</arm_group_label>
    <description>single molecular test ThyroSeq v.3 of collected tissue</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Afirma GEC</intervention_name>
    <description>Afirma GEC molecular test on collected thyroid tissue</description>
    <arm_group_label>Afirma GEC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ThyroSeq v.2</intervention_name>
    <description>ThyroSeq v.2 molecular test on collected thyroid tissue</description>
    <arm_group_label>ThyroSeq v.2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Afirma GSC</intervention_name>
    <description>Afirma GSC molecular test on collected thyroid tissue</description>
    <arm_group_label>Afirma GSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ThyroSeq v.3</intervention_name>
    <description>ThyroSeq v.3 molecular test on collected thyroid tissue</description>
    <arm_group_label>ThyroSeq v.3</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing thyroid fine needle aspiration (FNA) within the University of
        California, Los Angeles (UCLA) Health System
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a thyroid nodule who have a thyroid biopsy performed at UCLA health will
             be eligible for the study and consented if they agree to participate.

          -  Patients who have an indeterminate FNA biopsy result (Bethesda category 3 or 4) will
             be enrolled in the study if they agree to participate.

        Exclusion Criteria:

          -  Patients who do not have an indeterminate biopsy result (either patients who have a
             benign, insufficient, or malignant result).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masha Livhits, MC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Visiting Assistant Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Masha Livhits, MD</last_name>
    <phone>310-206-2781</phone>
    <email>mlivhits@mednet.ucla.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masha Livhits, MD</last_name>
      <phone>310-206-2781</phone>
      <email>mlivhits@mednet.ucla.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cibas ES, Ali SZ; NCI Thyroid FNA State of the Science Conference. The Bethesda System For Reporting Thyroid Cytopathology. Am J Clin Pathol. 2009 Nov;132(5):658-65. doi: 10.1309/AJCPPHLWMI3JV4LA. Review.</citation>
    <PMID>19846805</PMID>
  </reference>
  <reference>
    <citation>Lee L, How J, Tabah RJ, Mitmaker EJ. Cost-effectiveness of molecular testing for thyroid nodules with atypia of undetermined significance cytology. J Clin Endocrinol Metab. 2014 Aug;99(8):2674-82. doi: 10.1210/jc.2014-1219. Epub 2014 Mar 31.</citation>
    <PMID>24684467</PMID>
  </reference>
  <reference>
    <citation>Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, Walsh PS, Wilde JI, Zeiger MA, Lanman RB, Haugen BR. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012 Aug 23;367(8):705-15. doi: 10.1056/NEJMoa1203208. Epub 2012 Jun 25.</citation>
    <PMID>22731672</PMID>
  </reference>
  <reference>
    <citation>Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, Gooding WE, LeBeau SO, Ohori NP, Seethala RR, Tublin ME, Yip L, Nikiforova MN. Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology. Thyroid. 2015 Nov;25(11):1217-23. doi: 10.1089/thy.2015.0305. Epub 2015 Sep 10.</citation>
    <PMID>26356635</PMID>
  </reference>
  <reference>
    <citation>Wu JX, Lam R, Levin M, Rao J, Sullivan PS, Yeh MW. Effect of malignancy rates on cost-effectiveness of routine gene expression classifier testing for indeterminate thyroid nodules. Surgery. 2016 Jan;159(1):118-26. doi: 10.1016/j.surg.2015.05.035. Epub 2015 Oct 2.</citation>
    <PMID>26435428</PMID>
  </reference>
  <reference>
    <citation>Wu JX, Young S, Hung ML, Li N, Yang SE, Cheung DS, Yeh MW, Livhits MJ. Clinical Factors Influencing the Performance of Gene Expression Classifier Testing in Indeterminate Thyroid Nodules. Thyroid. 2016 Jul;26(7):916-22. doi: 10.1089/thy.2015.0505. Epub 2016 Jun 9.</citation>
    <PMID>27161519</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>February 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2016</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Nodule</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

